All In Biotech

Drug Trial Radar · NCT07775703

HS-20117-2 Injection in Patients With Advanced Solid Tumors

A Phase I Clinical Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of HS-20117-2 Injection in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 13, 2025

Primary completion

Dec 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a multicenter, open-label, Phase I clinical study designed to evaluate the pharmacokinetics, safety, and tolerability of HS-20117-2 in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • HS-20117-2 InjectionDrug

    Participants will receive subcutaneous injections of HS-20117-2 Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of PK parameters of HS-20117: CmaxTime frame: Up to Day 1 of Cycle 2(once every two weeks, each cycle is 14 days) or Day 1 of Cycle 3(once every three weeks, each cycle is 21 days)
  2. Evaluation of PK parameters of HS-20117: CtroughTime frame: Up to Day 1 of Cycle 2(once every two weeks, each cycle is 14 days) or Day 1 of Cycle 3(once every three weeks, each cycle is 21 days)
  3. Evaluation of PK parameters of HS-20117: AUC0-14dayTime frame: Up to 14 days(once every two weeks)
  4. Evaluation of PK parameters of HS-20117: AUC0-21dayTime frame: Up to 21 days(once every three weeks)
  5. Evaluation of the safety and tolerability of HS-20117-2 Injection in patients with advanced solid tumorsTime frame: Through study completion,up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.